Logo do repositório
 
Publicação

Real-world dapagliflozin treatment patterns in Portuguese patients with heart failure with reduced ejection fraction

2026-01Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorAndrade, Aurora
dc.contributor.authorGonçalves, Sara
dc.contributor.authorBatista, Ana
dc.contributor.authorTimóteo, Ana Teresa
dc.contributor.authorOliveira Soares, Ana
dc.contributor.authorFranco, Fátima
dc.contributor.authorSimões, Otília
dc.contributor.authorPardal, Marisa
dc.contributor.authorAlmeida, Mário
dc.contributor.authorLopes, Margarida
dc.contributor.authorBernardo, Filipa
dc.contributor.authorSilva Cardoso, José
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.pblSociedade Portuguesa de Cardiologia | Elsevier
dc.date.accessioned2026-01-22T10:31:02Z
dc.date.available2026-01-22T10:31:02Z
dc.date.issued2026-01
dc.descriptionPublisher Copyright: © 2025
dc.description.abstractIntroduction and objectives: Heart failure with reduced ejection fraction (HFrEF) poses a significant challenge to healthcare. While clinical trials have shown the therapeutic benefits of dapagliflozin in patients with HFrEF, it is essential to understand treatment patterns and patient characteristics in real-world settings. The EVOLUTION-HF study sought to address this gap by analyzing real-world data. Methods: EVOLUTION-HF is a retrospective cohort study conducted at eight sites in Portugal, which included patients who began treatment with dapagliflozin for HFrEF. Medical records were reviewed to collect information on the initiation date of dapagliflozin (the index date) and at the six- and 12-month follow-ups. Results: This study included 228 patients. The majority were male, with an average age of 65 years, a mean left ventricular ejection fraction of 29%, and 85% classified as NYHA class II. More prevalent comorbidities were dyslipidemia (59%) and arterial hypertension (56%). On the index date, baseline medications showed a high utilization of standard HFrEF therapies: 92% of patients received betablockers, 71% were on aldosterone antagonists, and 55% were taking angiotensin receptor-neprilysin inhibitors. At the end of the follow-up period, there was a significant increase in the dosage of beta-blockers and a decrease in the dosage of loop diuretics. A low discontinuation rate of 5% was observed for dapagliflozin. Conclusions: These findings support the established safety profile of dapagliflozin. The patient characteristics in the EVOLUTION-HF study closely resemble those in the DAPA-HF randomized trial. The observed treatment patterns indicate an optimization in guideline-directed medical therapy.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent1140781
dc.identifier.doi10.1016/j.repc.2025.08.007
dc.identifier.issn0870-2551
dc.identifier.otherPURE: 149273296
dc.identifier.otherPURE UUID: 48abfbdc-9178-4380-bf47-7b3b563a12ed
dc.identifier.otherScopus: 105025569259
dc.identifier.urihttp://hdl.handle.net/10362/199630
dc.identifier.urlhttps://www.scopus.com/pages/publications/105025569259
dc.language.isoeng
dc.peerreviewedyes
dc.subjectCardiovascular
dc.subjectDapagliflozin
dc.subjectHeart failure
dc.subjectReal-world
dc.subjectReduced ejection fraction
dc.subjectSGLT2i
dc.subjectCardiology and Cardiovascular Medicine
dc.titleReal-world dapagliflozin treatment patterns in Portuguese patients with heart failure with reduced ejection fractionen
dc.typejournal article
degois.publication.firstPage13
degois.publication.issue1
degois.publication.lastPage21
degois.publication.titleRevista Portuguesa de Cardiologia
degois.publication.volume45
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
1-s2.0-S0870255125003464-main.pdf
Tamanho:
1.09 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS - Artigos em revista nacional com arbitragem científica